Trajan Group Holdings Ltd · ASX:TRJ
Trajan — FY2025 Earnings Presentation
16 slides from Trajan's earnings presentation, Aug 28, 2025
Slide 1: August 28th 2025
August 28th 2025 Stephen Tomisich, Founder, CEO and Managing Director & Alister Hodges, CFO
Slide 2: Company Overview
Company Overview BUSINESS SEGMENTS Components & Consumables High precision products and services such as tubing, connections, injection devices, micro-fluidics, glass coating & pathology consumables. Capital Equipment Robotic workflow automation systems, software and spare parts for biological, food
Slide 3: FY2025 Financial Summary
FY2025 Financial Summary KEY POINTS REVENUE & EARNINGS FINANCIAL & CAPITAL DISCIPLINE • Revenue: Increased contribution from all Segments despite $3.9M biotech Group Revenue $166.5M Cash $ 11.9M syringe loss. [PCP: $155.0M] Up 7.4% [PCP $11.2M] Up 5.4% • nEBITDA: Improved despite several transient c
Slide 4: Trajan Products Embedded in Laboratories Globally
Trajan Products Embedded in Laboratories Globally As a leading, independent manufacturer, Trajan provides essential scientific tools and components relied on by analytical laboratories worldwide. There’s a strong chance that if you pick up a consumable or component in our field Trajan played a role
Slide 5: Strong Foundations Support Trajan’s Growth Trajectory
Strong Foundations Support Trajan’s Growth Trajectory Market Scale Momentum Precision Manufacturer In Region for Region Model Sustained global sales growth in North Preferred partner for global OEMs, Strategically located facilities near key America, EMEA, and Asia-Pacific. leveraging advanced engin
Slide 6: FY25 Highlights and Progress
FY25 Highlights and Progress HIGHLIGHTS PROGRESS Globalising the Capital Equipment Business: Expanding our capital We saw healthy expansion of our Food systems in Asia equipment offerings across our four core verticals - Environmental, Food, Clinical, Pacific. and Pharmaceutical - strengthening our
Slide 7: Versiti – Disruptive On-Line Measurement Technology
Versiti® – Disruptive On-Line Measurement Technology • The supply of pharmaceutical products such as cancer therapeutics can be time critical. In field evaluation by multiple users has highlighted the ease of use and robustness: • Products must be laboratory tested prior to batch “It is a great syst
Slide 8: Components & Consumables
Components & Consumables Net Revenue: Proforma nEBITDA of $102.7M Gross Profit $34.9M Margin 41.6% (PCP:$96.2M) (PCP:41.1%) (PCP:$32.3M) . . . . . . . . . . . . . . • Return to historical growth trajectory in core consumables. omponents and onsumables • Emerging product lines such as coated well eve
Slide 9: Capital Equipment
Capital Equipment Net Revenue: Proforma nEBITDA of $58.6M Gross Profit $9.7M Margin 35.1% (PCP:$53.9M) (PCP:40.2%) (PCP:$9.7M) 30.2 29.9 28.7 27.1 27.6 26.3 22.9 • Globalisation of Capital Equipment segment drove 8.6 6.7 expansion into price sensitive emerging markets 5.3 5.1 5.6 3.9 4.6 4.1 particu
Slide 10: Disruptive Technologies
Disruptive Technologies Net Revenue: Proforma nEBITDA of $5.1M Gross Profit ($1.5M) Margin 57.0% (PCP:$4.9M) (PCP:52.7%) (PCP:($4.9M)) 3.5 10.0 3.0 3.0 2.9 8.0 2.7 2.7 2.6 2.5 6.0 2.2 2.2 2.0 4.0 1.5 2.0 • Microsampling is now on a breakeven run rate with a -0.5 building orderbook, including repeat
Slide 11: Cashflow Summary
Cashflow Summary June 2025 June 2024 ($M) ($M) • Movement in net working capital due to increase in Normalised EBITDA1 15.5 12.3 inventories $1.2M, increase in receivables $3.6M, increase in payable $1.9M and increase in deferred revenue $0.2M. Income tax payments (0.4) (1.8) • The movement in worki
Slide 12: Building Resilience in a Volatile Environment
Building Resilience in a Volatile Environment In an increasingly complex and uncertain geopolitical environment, Trajan has demonstrated both resilience and agility. Volatility: Resilience: • US and retaliatory tariffs • In Region-for-Region manufacturing strategy • Reduced US research funds • Rapid
Slide 13: Environment Social Governance
Environment Social Governance Trajan’s SG strategy is guided by its purpose — Science that benefits people — with a commitment to ethical, responsible, and sustainable growth that delivers positive impacts across healthcare, environmental testing, and food safety globally. KEY PROGRESS IN FY25: Esta
Slide 14: Drivers for Continued Growth
Drivers for Continued Growth • Strong FY26 starting position: Entering the year with a strengthened balance sheet, robust demand signals, and momentum across core and emerging markets. • Resilient platform: Diverse global footprint, broad customer base, and product mix position Trajan to navigate ma
Slide 15: Disclaimer
Disclaimer The material in this presentation is general background information about Trajan Group Holdings Limited (Trajan) and is current at the date of the presentation, 28th August 2025. The information in the presentation is provided for information purposes only, is in summary form and does not
Slide 16: www.trajanscimed.com
= TRAJAN | Science that benefits people www.trajanscimed.com